James Healy, MD, PhD

General Partner

Jim Healy, MD, PhD, has over 20 years of experience in biomedical research, development and finance. He joined Sofinnova in 2000 as a General Partner, and specializes in funding clinical stage pharmaceuticals. Jim has financed and served on the board of eight companies which received drug approvals from either the FDA or EMA. He was an early investor and board member of eight companies which subsequently completed initial public offerings and seven companies that have been acquired.

Previous investments and board memberships include Cellective (acquired by AstraZeneca), Cotherix (CTRX, acquired by Actelion), Movetis (MOVE, acquired by Shire), NextWave (acquired by Pfizer), Novacea (NOVC, merged with Transcept), Preglem (acquired by Gideon Richter) and Prestwick (acquired by Biovail). Jim presently serves on the board of directors of Amarin (AMRN), Auris Medical, Intermune (ITMN) and is the Chairman of the Board at both Hyperion (HPTX) and Kalobios (KBIO). He also serves on the board of directors of various private companies.

In 2011 Jim won the IBF Risk Master Innovator Award for his investment in Amarin. He was listed as a leading “young and proven” biotech venture capitalists in 2012 by Xconomy, and was named as one of the top life science investors of 2013 by Forbes Magazine. Jim currently serves on the Board of Directors of the National Venture Capital Association which represents and serves the US venture capital industry.

Previously, Jim served as a member of the Executive Board of the College of Letters and Science at the University of California at Berkeley and has lectured on entrepreneurship at Stanford University. Prior to Sofinnova, Jim worked at Bayer (Miles), Sanderling, and consulted at ISTA Pharmaceuticals.

Jim graduated with a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California at Berkeley where he graduated with Honors and received a Departmental Citation. Jim received his MD and PhD in Immunology from Stanford University School of Medicine through the NIH Medical Scientist Training Program. He was a Beckman Scholar, received a Novartis Bursary Award and performed neuroscience research at the University of Virginia School of Medicine. Jim has authored or co-authored thirteen peerreviewed articles and invited reviews, including three papers published in Nature. He lived in Denmark for two years, speaks fluent Danish, enjoys mountaineering and is now taking up cross country skiing.

Assistant: Cassandra Fabel. Email: cassie(at)sofinnova.com.


(650) 681-8422


Representative Investments